hims and hers glp-1 A New Era of Weight Management is Coming to & Hims & Hers Health shares

doi: 10.1038/s41419-021-04142-4 35

Monjouro/Zepbound is a GIP (glucose-dependent insulinotropic polypeptide) and GLP - 1 receptor agonist

Brief Introduction: Cagrilintide is a novel long-acting acylated amylin analog that acts as a non-selective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist

BPC-157 came off the FDA Category 2 list effective April 23, 2026, and is one of the seven peptides under PCAC review for 503A compounding eligibility in July 2026

We know when we manage our patients with type 2 diabetes, we not only need to be concerned about glycemic control, but also about reducing cardiometabolic risk as well as weight reduction since most of our patients are overweight or obese, Juan P

2011 Aug;56(8):2349-53